Corporate & Background
About Divis
Vision & Mission
Milestones & Awards
Key People
 Custom Manufacturing
 Business & Products
 Facilities & Strengths
 Ethics & Values
 Regulatory Submissions
 Investors & Financials
 Careers
 Locations & Contact
 Media Center
 Enquiry
 Home
     Our Nutraceuticals website
      News & Events

 Divi’s Labs earns a PAT of Rs.129 crores for Q4
 Divi’s Labs earns an Income of Rs.649 crores for 9M of FY10
 Divis Labs earns an Income of Rs.445 crores in H1 of FY10
 Divi’s Labs earns an Income of Rs.218 crores in Q1
 Divi’s Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus
 Divi’s Labs PAT for 9 months
grows by 21% to Rs.309 crores
 Divi’s Labs PAT for Q2
grows by 49% to Rs.135 crores
 Divi’s Labs PAT for Q1
grows by 45% to Rs.94 crores
 Divi’s Labs PAT for FY08
grows by 87% to Rs.348 crores
 Divi’s Labs PAT for Q3
grows by 216% to Rs.99 crores
 Divi’s Labs PAT for Q2
grows by 204% to Rs.91 crores
 Divi’s Labs PAT for Q1
grows by 153% to Rs.65 crores
 Divi’s Labs PAT for FY07
grows by 167% to Rs.186 crores
 Divi’s Labs Q3 total income
 grows by 38% to Rs.152 crores
 Divis successful US-FDA
 inspection for Unit II
 Divi’s Labs Q2 total income
 grows by 97% to Rs.165 crores.
 Divi's Labs Q1 total income
 grows by 142% at Rs.165
 crores
 Divi's Laboratories earns
a net of 70 crores on an income
of Rs.392 crores in FY06
 Divi's gets nod for pharma SEZ
 Divis Laboratories earns a
 PBT of Rs.43 Crores in
 First-Half of FY06
 Divis Laboratories earns a
 total income of Rs.68
 Crores in Q1 of FY06
 Divis Laboratories earns a
 total income of Rs.365
 Crores in FY05
 Divis Laboratories earns a
 Net of Rs.105 Crores in Q3
 Divis Laboratories earns a
 PBT of Rs.45 Crores in
 First-Half of FY05
 Divis Laboratories earns a
 Net of Rs.14 Crores in Q1

Established in the year 1990, with Research & Development as its prime fundamental, Divis Laboratories focussed on developing new processes for the production of Active Pharma Ingredients (APIs) & Intermediates. The company in a matter of short time expanded its breadth of operations to provide complete turnkey solutions to the domestic Indian pharmaceutical industry.

With five years of experience, expertise and a proven track-record of helping many companies with its turn-key and consulting strengths, Divis Laboratories established its first manufacturing facility in 1995.

Built on a 500 acre site at Hyderabad (Unit-I). the plant comprises of 13 multi-purpose production blocks and has space for further growth and expansion.

Divis Laboratories set up its second manufacturing facility at Visakhapatnam (Unit-II). in the year 2002 on a 350 acre site. The site has 14 multi purpose production blocks.

Both the facilities are primarily engaged in the manufacture of:
   Active Pharmaceutical Ingredients (APIs) & Intermediates for Generics
   Custom Synthesis of API's and Advanced intermediates for discovery compounds for
   pharma giants
   Building blocks for Peptides
   Building blocks for Nucleotides
   Carotenoids
   Chiral ligands

Complete cGMP guidelines are complied with in both the plants. Our Unit-1 at Hyderabad was successfully inspected by the US FDA during September 2000, in April 2004 and in February 2008. Our Unit-2 at Visakhapatnam was successfully inspected by the US FDA during November 2006. Divis also undertakes FTE/Contract Research on process development for discovering new compounds for leading MNCs across the world and partners with them for the supply of APIs. The company is global in its outlook and benchmarks its quality standards to the best in the world.

top
Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved     Web design london